Central nervous system metastases involving the brain parenchyma and leptomeninges are common in non-small cell lung cancer, especially cases withEGFRmutations. Here, we examine treatment options forEGFR-mutated non-small cell lung cancer patients with central nervous system metastases, highlighting the efficacy of third-generationEGFR-targeted tyrosine kinase inhibitors. Furthermore, we examine the interplay of this modality with chemotherapy or radiation in resistant cases.
中枢神经系统转移,包括脑实质和软脑膜转移,在非小细胞肺癌中较为常见,尤其是在携带EGFR突变的病例中。本文探讨了针对伴有中枢神经系统转移的EGFR突变非小细胞肺癌患者的治疗方案,重点分析了第三代EGFR靶向酪氨酸激酶抑制剂的疗效。此外,我们还研究了在耐药病例中,该治疗方式与化疗或放疗的相互作用。